MAPT H1 haplotype is associated with enhanced α-synuclein deposition in dementia with Lewy bodies

Neurobiology of Aging

Volumn 34, Issue 3, 2013, Pages 936-942

  Colom Cadena, Martí ^a,b   Gelpi, Ellen ^c   Martí, María J ^b,c   Charif, Sara ^c   Dols Icardo, Oriol ^a,b   Blesa, Rafael ^a,b   Clarimón, Jordi ^a,b   Lleó, Alberto ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

synuclein; Alzheimer's disease; Dementia with Lewy bodies; MAPT haplotype; Parkinson's disease dementia; Tau

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; TAU PROTEIN;

ADULT; AGED; ALLELE; APOE GENE; ARTICLE; BRAIN REGION; BRAIN STEM; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; DEMENTIA; DISEASE ASSOCIATION; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN TISSUE; LEWY BODY; MALE; MAPT H1 GENE; NEUROPATHOLOGY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; SCORING SYSTEM; SYNUCLEINOPATHY;

AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; APOLIPOPROTEIN E4; BRAIN; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; LEWY BODIES; LEWY BODY DISEASE; MALE; TAU PROTEINS;

EID: 84870569238     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2012.06.015     Document Type: Article

References (39)

1. Alafuzoff I., Pikkarainen M., Al-Sarraj S., Arzberger T., Bell J., Bodi I., Bogdanovic N., Budka H., Bugiani O., Ferrer I., Gelpi E., Giaccone G., Graeber M.B., Hauw J.J., Kamphorst W., King A., Kopp N., Korkolopoulou P., Kovács G.G., Meyronet D., Parchi P., Patsouris E., Preusser M., Ravid R., Roggendorf W., Seilhean D., Streichenberger N., Thal D.R., Kretzschmar H. Interlaboratory comparison of assessments of Alzheimer disease-related lesions: a study of the BrainNet Europe Consortium. J. Neuropathol. Exp. Neurol. 2006, 65:740-757.
2. Badiola N., de Oliveira R.M., Herrera F., Guardia-Laguarta C., Gonçalves S.A., Pera M., Suárez-Calvet M., Clarimon J., Outeiro T.F., Lleó A. Tau enhances α-synuclein aggregation and toxicity in cellular models of synucleinopathy. PLoS One 2011, 6:e26609.
3. Baker M., Litvan I., Houlden H., Adamson J., Dickson D., Perez-Tur J., Hardy J., Lynch T., Bigio E., Hutton M. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum. Mol. Genet. 1999, 8:711-715.
4. Balasa M., Gelpi E., Antonell A., Rey M.J., Sánchez-Valle R., Molinuevo J.L., Lladó A. Clinical features and APOE genotype of pathologically proven early-onset Alzheimer disease. Neurology 2011, 76:1720-1725. Neurological Tissue Bank/University of Barcelona/Hospital Clínic NTB/UB/HC Collaborative Group.
5. Botta-Orfila T., Ezquerra M., Ríos J., Fernández-Santiago R., Cervantes S., Samaranch L., Pastor P., Martí M.J., Muñoz E., Valldeoriola F., Aguilar M., Calopa M., Hernández-Vara J., Tolosa E. Lack of interaction of SNCA and MAPT genotypes in Parkinson's disease. Eur. J. Neurol. 2011, 18:e32.
6. Braak H., Alafuzoff I., Arzberger T., Kretzschmar H., Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006, 112:389-404.
7. Caffrey T.M., Joachim C., Paracchini S., Esiri M.M., Wade-Martins R. Haplotype-specific expression of exon 10 at the human MAPT locus. Hum. Mol. Genet. 2006, 15:3529-3537.
8. Caffrey T.M., Wade-Martins R. Functional MAPT haplotypes: bridging the gap between genotype and neuropathology. Neurobiol. Dis. 2007, 27:1-10.
9. Charlesworth G., Gandhi S., Bras J.M., Barker R.A., Burn D.J., Chinnery P.F., Gentleman S.M., Guerreiro R., Hardy J., Holton J.L., Lees A., Morrison K., Sheerin U.M., Williams N., Morris H., Revesz T., Wood N.W. Tau acts as an independent genetic risk factor in pathologically proven PD. Neurobiol. Aging 2012, 33:e7-e11.
10. Clarimón J., Molina-Porcel L., Gómez-Isla T., Blesa R., Guardia-Laguarta C., González-Neira A., Estorch M., Ma Grau J., Barraquer L., Roig C., Ferrer I., Lleó A. Early-onset familial lewy body dementia with extensive tauopathy: a clinical, genetic, and neuropathological study. J. Neuropathol. Exp. Neurol. 2009, 68:73-82.
11. Clinton L.K., Blurton-Jones M., Myczek K., Trojanowski J.Q., LaFerla F.M. Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J. Neurosci. 2010, 30:7281-7289.
12. Compta Y., Parkkinen L., O'Sullivan S.S., Vandrovcova J., Holton J.L., Collins C., Lashley T., Kallis C., Williams D.R., de Silva R., Lees A.J., Revesz T. Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?. Brain 2011, 134:1493-1505.
13. Elbaz A., Ross O.A., Ioannidis J.P., Soto-Ortolaza A.I., Moisan F., Aasly J., Annesi G., Bozi M., Brighina L., Chartier-Harlin M.C., Destée A., Ferrarese C., Ferraris A., Gibson J.M., Gispert S., Hadjigeorgiou G.M., Jasinska-Myga B., Klein C., Krüger R., Lambert J.C., Lohmann K., van de Loo S., Loriot M.A., Lynch T., Mellick G.D., Mutez E., Nilsson C., Opala G., Puschmann A., Quattrone A., Sharma M., Silburn P.A., Stefanis L., Uitti R.J., Valente E.M., Vilariño-Güell C., Wirdefeldt K., Wszolek Z.K., Xiromerisiou G., Maraganore D.M., Farrer M.J. Independent and joint effects of the MAPT and SNCA genes in Parkinson disease. Ann. Neurol. 2011, 69:778-792. Genetic Epidemiology of Parkinson's Disease (GEO-PD) Consortium.
14. Giasson B.I., Forman M.S., Higuchi M., Golbe L.I., Graves C.L., Kotzbauer P.T., Trojanowski J.Q., Lee V.M. Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 2003, 300:636-640.
15. Goris A., Williams-Gray C.H., Clark G.R., Foltynie T., Lewis S.J., Brown J., Ban M., Spillantini M.G., Compston A., Burn D.J., Chinnery P.F., Barker R.A., Sawcer S.J. Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann. Neurol. 2007, 62:145-153.
16. Guardia-Laguarta C., Pera M., Clarimón J., Molinuevo J.L., Sánchez-Valle R., Lladó A., Coma M., Gómez-Isla T., Blesa R., Ferrer I., Lleó A. Clinical, neuropathologic, and biochemical profile of the amyloid precursor protein I716F mutation. J. Neuropathol. Exp. Neurol. 2010, 69:53-59.
17. Hardy J. Genetic analysis of pathways to Parkinson disease. Neuron 2010, 68:201-206.
18. Houlden H., Baker M., Morris H.R., MacDonald N., Pickering-Brown S., Adamson J., Lees A.J., Rossor M.N., Quinn N.P., Kertesz A., Khan M.N., Hardy J., Lantos P.L., St.George-Hyslop P., Munoz D.G., Mann D., Lang A.E., Bergeron C., Bigio E.H., Litvan I., Bhatia K.P., Dickson D., Wood N.W., Hutton M. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology 2001, 56:1702-1706.
19. Nalls M.A., Plagnol V., Hernandez D.G., Sharma M., Sheerin U.M., Saad M., Simon-Sanchez J., Schulte C., Lesage S., Sveinbjornsdottir S., Stefansson K., Martinez M., Hardy J., Heutink P., Brice A., Gasser T., Singleton A.B., Wood N.W. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet 2011, 377:641-649. International Parkinson Disease Genomics Consortium.
20. Kuusisto E., Parkkinen L., Alafuzoff I. Morphogenesis of Lewy bodies: dissimilar incorporation of alpha-synuclein, ubiquitin, and p62. J. Neuropathol. Exp. Neurol. 2003, 62:1241-1253.
21. Kwok J.B., Teber E.T., Loy C., Hallupp M., Nicholson G., Mellick G.D., Buchanan D.D., Silburn P.A., Schofield P.R. Tau haplotypes regulate transcription and are associated with Parkinson's disease. Ann. Neurol. 2004, 55:329-334.
22. Lippa C.F., Duda J.E., Grossman M., Hurtig H.I., Aarsland D., Boeve B.F., Brooks D.J., Dickson D.W., Dubois B., Emre M., Fahn S., Farmer J.M., Galasko D., Galvin J.E., Goetz C.G., Growdon J.H., Gwinn-Hardy K.A., Hardy J., Heutink P., Iwatsubo T., Kosaka K., Lee V.M., Leverenz J.B., Masliah E., McKeith I.G., Nussbaum R.L., Olanow C.W., Ravina B.M., Singleton A.B., Tanner C.M., Trojanowski J.Q., Wszolek Z.K. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 2007, 68:812-819. DLB/PDD Working Group.
23. McKeith I.G., Dickson D.W., Lowe J., Emre M., O'Brien J.T., Feldman H., Cummings J., Duda J.E., Lippa C., Perry E.K., Aarsland D., Arai H., Ballard C.G., Boeve B., Burn D.J., Costa D., Del Ser T., Dubois B., Galasko D., Gauthier S., Goetz C.G., Gomez-Tortosa E., Halliday G., Hansen L.A., Hardy J., Iwatsubo T., Kalaria R.N., Kaufer D., Kenny R.A., Korczyn A., Kosaka K., Lee V.M., Lees A., Litvan I., Londos E., Lopez O.L., Minoshima S., Mizuno Y., Molina J.A., Mukaetova-Ladinska E.B., Pasquier F., Perry R.H., Schulz J.B., Trojanowski J.Q., Yamada M. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005, 65:1863-1872. Consortium on DLB.
24. Mirra S.S., Heyman A., McKeel D., Sumi S.M., Crain B.J., Brownlee L.M., Vogel F.S., Hughes J.P., van Belle G., Berg L. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991, 41:479-486.
25. Montine T.J., Phelps C.H., Beach T.G., Bigio E.H., Cairns N.J., Dickson D.W., Duyckaerts C., Frosch M.P., Masliah E., Mirra S.S., Nelson P.T., Schneider J.A., Thal D.R., Trojanowski J.Q., Vinters H.V., Hyman B.T. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol. 2012, 123:1-11.
26. Myers A.J., Pittman A.M., Zhao A.S., Rohrer K., Kaleem M., Marlowe L., Lees A., Leung D., McKeith I.G., Perry R.H., Morris C.M., Trojanowski J.Q., Clark C., Karlawish J., Arnold S., Forman M.S., Van Deerlin V., de Silva R., Hardy J. The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts. Neurobiol. Dis. 2007, 25:561-570.
27. Pittman A.M., Myers A.J., Abou-Sleiman P., Fung H.C., Kaleem M., Marlowe L., Duckworth J., Leung D., Williams D., Kilford L., Thomas N., Morris C.M., Dickson D., Wood N.W., Hardy J., Lees A.J., de Silva R. Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration. J. Med. Genet. 2005, 42:837-846.
28. Setó-Salvia N., Clarimón J., Pagonabarraga J., Pascual-Sedano B., Campolongo A., Combarros O., Mateo J.I., Regaña D., Martínez-Corral M., Marquié M., Alcolea D., Suárez-Calvet M., Molina-Porcel L., Dols O., Gómez-Isla T., Blesa R., Lleó A., Kulisevsky J. Dementia risk in Parkinson disease: disentangling the role of MAPT haplotypes. Arch. Neurol. 2011, 68:359-364.
29. Simón-Sánchez J., Schulte C., Bras J.M., Sharma M., Gibbs J.R., Berg D., Paisan-Ruiz C., Lichtner P., Scholz S.W., Hernandez D.G., Krüger R., Federoff M., Klein C., Goate A., Perlmutter J., Bonin M., Nalls M.A., Illig T., Gieger C., Houlden H., Steffens M., Okun M.S., Racette B.A., Cookson M.R., Foote K.D., Fernandez H.H., Traynor B.J., Schreiber S., Arepalli S., Zonozi R., Gwinn K., van der Brug M., Lopez G., Chanock S.J., Schatzkin A., Park Y., Hollenbeck A., Gao J., Huang X., Wood N.W., Lorenz D., Deuschl G., Chen H., Riess O., Hardy J.A., Singleton A.B., Gasser T. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Genet. 2009, 41:1308-1312.
30. Skipper L., Wilkes K., Toft M., Baker M., Lincoln S., Hulihan M., Ross O.A., Hutton M., Aasly J., Farrer M. Linkage disequilibrium and association of MAPT H1 in Parkinson disease. Am. J. Hum. Genet. 2004, 75:669-677.
31. Thal D.R., Rüb U., Orantes M., Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002, 58:1791-1800.
32. Tobin J.E., Latourelle J.C., Lew M.F., Klein C., Suchowersky O., Shill H.A., Golbe L.I., Mark M.H., Growdon J.H., Wooten G.F., Racette B.A., Perlmutter J.S., Watts R., Guttman M., Baker K.B., Goldwurm S., Pezzoli G., Singer C., Saint-Hilaire M.H., Hendricks A.E., Williamson S., Nagle M.W., Wilk J.B., Massood T., Laramie J.M., DeStefano A.L., Litvan I., Nicholson G., Corbett A., Isaacson S., Burn D.J., Chinnery P.F., Pramstaller P.P., Sherman S., Al-hinti J., Drasby E., Nance M., Moller A.T., Ostergaard K., Roxburgh R., Snow B., Slevin J.T., Cambi F., Gusella J.F., Myers R.H. Haplotypes and gene expression implicate the MAPT region for Parkinson disease: the GenePD Study. Neurology 2008, 71:28-34.
33. Uchikado H., Lin W.L., DeLucia M.W., Dickson D.W. Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy. J. Neuropathol. Exp. Neurol. 2006, 65:685-697.
34. Van der Putten H., Wiederhold K.H., Probst A., Barbieri S., Mistl C., Danner S., Kauffmann S., Hofele K., Spooren W.P., Ruegg M.A., Lin S., Caroni P., Sommer B., Tolnay M., Bilbe G. Neuropathology in mice expressing human alpha-synuclein. J. Neurosci. 2000, 20:6021-6029.
35. Vilariño-Güell C., Soto-Ortolaza A.I., Rajput A., Mash D.C., Papapetropoulos S., Pahwa R., Lyons K.E., Uitti R.J., Wszolek Z.K., Dickson D.W., Farrer M.J., Ross O.A. MAPT H1 haplotype is a risk factor for essential tremor and multiple system atrophy. Neurology 2011, 76:670-672.
36. Wider C., Ross O.A., Nishioka K., Heckman M.G., Vilariño-Güell C., Jasinska-Myga B., Erketin-Taner N., Rademakers R., Graff-Radford N.R., Mash D.C., Papapetropoulos S., Duara R., Uchikado H., Wszolek Z.K., Farrer M.J., Dickson D.W. An evaluation of the impact of MAPT, SNCA and APOE on the burden of Alzheimer's and Lewy body pathology. J. Neurol. Neurosurg. Psychiatry 2012, 83:424-429.
37. Wider C., Vilariño-Güell C., Heckman M.G., Jasinska-Myga B., Ortolaza-Soto A.I., Diehl N.N., Crook J.E., Cobb S.A., Bacon J.A., Aasly J.O., Gibson J.M., Lynch T., Uitti R.J., Wszolek Z.K., Farrer M.J., Ross O.A. SNCA, MAPT, and GSK3B in Parkinson disease: a gene-gene interaction study. Eur. J. Neurol. 2011, 18:876-881.
38. Williams-Gray C.H., Evans J.R., Goris A., Foltynie T., Ban M., Robbins T.W., Brayne C., Kolachana B.S., Weinberger D.R., Sawcer S.J., Barker R.A. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 2009, 132:2958-2969.
39. Zabetian C.P., Hutter C.M., Factor S.A., Nutt J.G., Higgins D.S., Griffith A., Roberts J.W., Leis B.C., Kay D.M., Yearout D., Montimurro J.S., Edwards K.L., Samii A., Payami H. Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's disease. Ann. Neurol. 2007, 62:137-144.